Clinical trials: Crohn's
Crohn's Disease
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels.
- Trial name
- U-EMPOWER (NCT06332534)
- Testing
- Upadacitinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 111 people
- Sponsor
- AbbVie
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with…
- Trial name
- SIBERITE-1 (NCT06819878)
- Testing
- Afimkibart
- Where
- 375 sites in United States, Argentina and 36 more
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants…
- Trial name
- CHROMA CD (NCT06958536)
- Testing
- brivekimig
- Where
- 66 sites in United States, Australia and 10 more
- Volunteers
- 99 people
- Sponsor
- Sanofi
Ulcerative Colitis, Crohn's Disease
A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn's Disease (CD). This is happening because people are living longer and because more people overall are developing UC or…
- Trial name
- NCT07250815
- Testing
- No intervention
- Where
- United States
- Sponsor
- Takeda
Crohn Disease
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term…
- Trial name
- DUET ENCORE-CD (NCT07577843)
- Testing
- JNJ-78934804, Guselkumab
- Where
- 252 sites in United States, Argentina and 28 more
- Volunteers
- 460 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD).
- Trial name
- SPECIFI-CD (NCT06637631)
- Testing
- SAR441566
- Where
- 141 sites in United States, Argentina and 22 more
- Volunteers
- 105 people
- Sponsor
- Sanofi
Enteric Hyperoxaluria
Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).
A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of TRA16 Administered Orally in Patients with Enteric Hyperoxaluria (EH).
- Trial name
- NCT07871669
- Testing
- TRA16
- Volunteers
- 30 people
- Sponsor
- Wuhan Kangfude Urolithiasis Research Institute Co., Ltd.
Ulcerative Colitis, Crohn's Disease
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time.
- Trial name
- NCT06405087
- Testing
- Vedolizumab SC, No Intervention
- Where
- 47 sites in United States, Belgium and 12 more
- Volunteers
- 70 people
- Sponsor
- Takeda
Crohn's Disease
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years.
- Trial name
- COMPASS-CD (NCT04809363)
- Testing
- CDPATH™, Blood Draw
- Where
- 44 sites in United States
- Volunteers
- 241 people
- Sponsor
- Takeda
Inflammatory Bowel Diseases, Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's…
- Trial name
- GARNET (NCT06226883)
- Testing
- MORF-057
- Where
- 225 sites in United States, Australia and 26 more
- Volunteers
- 385 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Crohn Disease
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely…
- Trial name
- NCT07483099
- Testing
- LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
- Where
- 70 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Crohns Disease
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.
- Trial name
- NCT04397263
- Testing
- Guselkumab
- Where
- 25 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Janssen Pharmaceutical K.K.
Ulcerative Colitis, Ulcerative Colitis Chronic
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD).
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
- Trial name
- SHINE-ON (NCT04844606)
- Testing
- Mirikizumab
- Where
- 69 sites in United States, Austria and 14 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention.
- Trial name
- AMAY (NCT05509777)
- Testing
- Mirikizumab
- Where
- 81 sites in United States, Austria and 14 more
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and…
- Trial name
- COMMIT-CD (NCT06937099)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 183 sites in United States, Austria and 20 more
- Volunteers
- 290 people
- Sponsor
- Eli Lilly and Company
Crohn Disease, Colitis, Ulcerative
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).
- Trial name
- NCT05668013
- Testing
- TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
- Where
- 93 sites in United States, Austria and 14 more
- Volunteers
- 247 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Moderately to Severely Active Crohns Disease
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
- Trial name
- SIBERITE-PEDS (NCT07298421)
- Testing
- Afimkibart
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease, Ulcerative Colitis
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing, and often disabling condition characterized by inflammation of the gastrointestinal tract.
- Trial name
- TATOO (NCT07421258)
- Where
- 5 sites in China, France and 1 more
- Volunteers
- 1,638 people
- Sponsor
- AbbVie
Psoriasis, Colitis, Ulcerative
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the…
- Conditions
- Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
- Trial name
- NCT07654751
- Testing
- Breast Milk Sample Collection, Guselkumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Crohn Disease, Fibrostenotic Crohn's Disease
Artificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes
The goal of this retrospective observational study is to learn whether artificial intelligence-based digital pathology can measure intestinal fibrosis and help identify patients with Crohn's disease who may be at greater risk of…
- Conditions
- Crohn Disease, Fibrostenotic Crohn's Disease, CD - Crohn's Disease
- Trial name
- AIFOR-CD (NCT07795476)
- Testing
- Ph-FCS(Muc) fibrosis severity Digital Pathology biomarker
- Where
- 2 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PharmaNest, Inc